

REMARKS

This responds to the Office's communication dated 16 April 2008. A 1 month extension of time is requested.

Claims 53-56 have been rejected under 35 USC 112, ¶1 allegedly for failing to be enabled by the information set out in the specification. As PDE4 inhibitors, the claimed compounds demonstrate activity in the assays set out in specification. And as such the various diseases recited in claims 53-56 can reasonably be said to be therapeutic uses for the various and numerous compound of formula (I). But rather than attempt to traverse the collection of bases underpinning the examiner's conclusion, applicants elect to progress the compound per se and formulation claims to issuance, while reserving the right to pursue use claims in a separate application.

Parenthetically, applicants elect to cancel claim 57 as well, as it covers a composition for treating the diseases in claims 53-56, to which the examiner has objected.

New claim 63 has been added to specifically recite a compound previously named in a list of compounds in claim 42.

Applicants request that the amendments to the claims be entered into the record.

This reply is intended to distinctly and specifically point out presumed errors in the Examiner's Action, to respond to every ground of objection and rejection, and to advance this case to allowance.

In view of the above remarks, reconsideration of this application is requested. Should the Examiner have any questions or wish to discuss any aspect of this case, the Examiner is encouraged to call the undersigned agent at the number below.

Respectfully submitted,

/JamesMKanagy/

James M. Kanagy
Attorney for Applicant
Registration No. 29,550

Serial No.: 10/540,371
Group Art Unit No.: 1625

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5014
Facsimile (610) 270-5090